share_log

Citigroup Maintains Buy on Cogent Biosciences, Raises Price Target to $13

Moomoo 24/7 ·  Feb 26 11:45

Citigroup analyst David Lebowitz maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $11 to $13.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment